Company profile
Mallinckrodt
Specialty pharma -- reorganizing post-Chapter-11 (targeting a 2026 NYSE relisting as "Keenova"), ticker deliberately left null given the transitional OTC listing
Privately held: no public share price · Ireland
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
nitric oxide(INOmax) | Approved | Nitric oxideOther | Hypertension |
Repository corticotropin (Acthar Gel)(Acthar Gel) | Approved | Melanocortin receptors (primarily MC2R on the adrenal cortex) · Melanocortin 2 receptor (MC2R) (agonist)Peptide | Systemic Lupus ErythematosusRheumatoid ArthritisMultiple SclerosisEpilepsy |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.